Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dept. of Nuclear Medicine, Munich, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of schizophrenia (currently unmedicated)
Subjects at risk for the development of schizophrenia (prodromal symptoms)
Healthy subjects
Written informed consent

Exclusion criteria

Neurological or severe somatic disorders
Women during pregnancy or lactation
Occupational exposition to radiation > 15mSv
Medication known to interfere with IBZM
Contraindications for the use of amphetamine challenge

Treatment and study plan

IBZM-SPECT (bolus and constant infusion paradigm)

Procedure

single IBZM-SPECT assessment at study inclusion

Primary outcomes

dopamine receptor availability

Time frame: cross-sectional

Sponsors and collaborators

Lead sponsor

Ludwig-Maximilians - University of Munich

Other

Registry information

Important dates

Study start: 2004
Primary completion: 2007
Study completion: 2007
First posted: Sep 14, 2005
Registry last updated: May 7, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed